000310293 001__ 310293
000310293 005__ 20260305150916.0
000310293 0247_ $$2doi$$a10.1016/j.ejca.2026.116600
000310293 0247_ $$2pmid$$apmid:41780180
000310293 0247_ $$2ISSN$$a0959-8049
000310293 0247_ $$2ISSN$$a0014-2964
000310293 0247_ $$2ISSN$$a1879-0852
000310293 0247_ $$2ISSN$$a(1990)
000310293 0247_ $$2ISSN$$a1879-2995
000310293 0247_ $$2ISSN$$a(1965)
000310293 037__ $$aDKFZ-2026-00516
000310293 041__ $$aEnglish
000310293 082__ $$a610
000310293 1001_ $$aJudickiene, Julija$$b0
000310293 245__ $$aPretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients.
000310293 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2026
000310293 3367_ $$2DRIVER$$aarticle
000310293 3367_ $$2DataCite$$aOutput Types/Journal article
000310293 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772719749_1921026
000310293 3367_ $$2BibTeX$$aARTICLE
000310293 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310293 3367_ $$00$$2EndNote$$aJournal Article
000310293 520__ $$aCheckpoint inhibitor therapy with PD-1/PD-L1-antibodies has significant benefits in non-small-cell lung cancer treatment even in advanced stage IVA/B. While PD-L1 expression in tumor is a weak but relevant predictor of treatment response, impact and interaction of potential prognostic factors like ECOG status, LDH-levels, CRP-levels, and genetic mutations remain so far undefined. This study aims to identify pretherapeutic factors that could help estimate outcome of NSCLC patients undergoing chemoimmunotherapy or mono-immunotherapy.In our Comprehensive Cancer Centre we retrospectively analyzed two selective patient groups undergoing treatment with mono- or chemoimmunotherapy. 'Super responders' with long-term survival longer than 24 months were contrasted against primary progressors with progression-free survival of less than 10 months. Factors were analyzed with univariate and multivariate statistical methods.In 120 patients fulfilling the inclusion criteria we found signals for five factors with impact on overall survival in univariate analyses: ECOG-status, PD-L1 TPS, serum LDH, serum CRP and KEAP-1 mutation. Multivariate analyses confirmed independent impact. As a confirmatory analysis the impact of these factors on progression-free survival was investigated. Comparable impact was supported by univariate and multivariate analysis.A detailed prognostic factor analysis for overall survival and progression-free survival in selected groups of advanced non-small-cell lung cancer patients under chemo- or mono-immunotherapy identified five independent parameters: initial ECOG of zero, non-elevated LDH, non-elevated CRP, pretreatment PD-L1 positivity and absence of KEAP1-mutation. Our findings are especially helpful of estimating early treatment failure with aggressive lung cancer progression. This important investigation will be prospectively confirmed in a larger, more unselected population at our Cancer Centre.
000310293 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000310293 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310293 650_7 $$2Other$$aLung cancer - NSCLC - stage IV - pretreatment prognostic factors - immunotherapy
000310293 7001_ $$aMetzenmacher, Martin$$b1
000310293 7001_ $$aZaun, Gregor$$b2
000310293 7001_ $$aWiesweg, Marcel$$b3
000310293 7001_ $$aMeschke, Dorothea E$$b4
000310293 7001_ $$aGuberina, Nika$$b5
000310293 7001_ $$aOezkan, Filiz$$b6
000310293 7001_ $$aHense, Jörg$$b7
000310293 7001_ $$0P:(DE-HGF)0$$aSchuler, Martin$$b8
000310293 7001_ $$aTheegarten, Dirk$$b9
000310293 7001_ $$aBolükbas, Servet$$b10
000310293 7001_ $$aStuschke, Martin$$b11
000310293 7001_ $$aEberhardt, Wilfried E E$$b12
000310293 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2026.116600$$gVol. 238, p. 116600 -$$p116600$$tEuropean journal of cancer$$v238$$x0959-8049$$y2026
000310293 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000310293 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000310293 9141_ $$y2026
000310293 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-11$$wger
000310293 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-11
000310293 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2025-11-11
000310293 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000310293 980__ $$ajournal
000310293 980__ $$aVDB
000310293 980__ $$aI:(DE-He78)ED01-20160331
000310293 980__ $$aUNRESTRICTED